Abatacept

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Abatacept
Klinički podaci
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 332348-12-6
ATC kod L04AA24
DrugBank DB01281
ChEMBL[1] CHEMBL1201823 YesY
Hemijski podaci
Formula ?
Farmakokinetički podaci
Poluvreme eliminacije 16,7 (12-23) dana
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Intravenozno, subkutano

Abatacept (Orencia) fuzioni protein je koji se sastoji od Fc regiona imunoglobulina IgG1 spojenog sa ekstracelularnim domenom CTLA-4. Ovaj molekul ima veću sposobnost vezivanja za CD80 (B7-1) nego za CD86 (B7-2). Abatacept je selektivni kostimulationi modulator koji inhibira kostimulaciju T ćelija. On se koristi za lečenje reumatoidnog artritisa u slučaju neadekvatnog responsa na anti-TNFα terapiju.[2][3][4][5][6][7][8][9][10][11][12][13]

Reference[uredi - уреди | uredi izvor]

  1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  2. Dall'Era M, Davis J: CTLA4Ig: a novel inhibitor of costimulation. Lupus. 2004;13(5):372-6. PMID 15230295
  3. Moreland L, Bate G, Kirkpatrick P: Abatacept. Nat Rev Drug Discov. 2006 Mar;5(3):185-6. PMID 16557658
  4. Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, Vratsanos G, Zhou Y, Moreland LW: Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006 Nov;33(11):2162-6. Epub 2006 Oct 1. PMID 17014006
  5. Weyand CM, Goronzy JJ: T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006 Apr;2(4):201-10. PMID 16932686
  6. Scheinfeld N: Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists. J Dermatolog Treat. 2006;17(4):229-34. PMID 16971318
  7. Maxwell LJ, Singh JA: Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010 Feb;37(2):234-45. Epub 2010 Jan 15. PMID 20080922
  8. Maxwell L, Singh JA: Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007277. PMID 19821401
  9. Nogid A, Pham DQ: Role of abatacept in the management of rheumatoid arthritis. Clin Ther. 2006 Nov;28(11):1764-78. PMID 17212998
  10. Hervey PS, Keam SJ: Abatacept. BioDrugs. 2006;20(1):53-61; discussion 62. PMID 16573350
  11. Reynolds J, Shojania K, Marra CA: Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. Pharmacotherapy. 2007 Dec;27(12):1693-701. PMID 18041889
  12. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41. PMC 3013709. PMID 21059682. doi:10.1093/nar/gkq1126. 
  13. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic acids research 36 (Database issue): D901–6. PMC 2238889. PMID 18048412. doi:10.1093/nar/gkm958. 

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).